Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Nilotinib Effective and Safe in Initial Treatment of Chronic Leukemia
(Posted: 12/28/2009, Updated: 09/06/2011) - Preliminary results from a phase III trial testing nilotinib (Tasigna) against imatinib mesylate (Gleevec) as first-line treatment for chronic-phase chronic myelogenous leukemia (CML) indicate that nilotinib is effective and safe as initial treatment for this disease.
- Chemotherapy Combination Improves Survival in Elderly Lung Cancer Patients
(Posted: 06/23/2010, Updated: 09/06/2011) - Survival can be improved in older patients with advanced non-small cell lung cancer (NSCLC) with the use of two chemotherapy drugs as opposed to a single agent.
- Zoledronic Acid Improves Early Breast Cancer Treatment
(Posted: 06/19/2008, Updated: 09/06/2011) - The addition of zoledronic acid (Zometa®) to adjuvant endocrine therapy in premenopausal women with early stage breast cancer significantly improves clinical outcomes beyond those achieved with endocrine therapy alone, according to findings presented at the 2008 ASCO meeting in Chicago.
- Cetuximab Combined with Oxaliplatin-Based Chemotherapy May Not Be Effective First-Line Treatment for Metastatic Colorectal Cancer
(Posted: 08/30/2011) - In a randomized phase III trial, the addition of the targeted therapy cetuximab to oxaliplatin and fluoropyrimidine chemotherapy did not prolong survival or time to disease progression of patients with advanced colorectal cancer. The results were published on June 5, 2011 in The Lancet.
- Ovarian Cancer Screening Method Fails to Reduce Deaths from the Disease
(Posted: 07/27/2011) - New results from the NCI-sponsored Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial show that screening for ovarian cancer with transvaginal ultrasound (TVU) and the CA-125 blood test did not result in fewer deaths from the disease compared with usual care.